Becaplermin - Biologic Drug Details

Summary for becaplermin

Tradenames:	1
High Confidence Patents:	1
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for becaplermin
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for becaplermin

Recent Clinical Trials for becaplermin

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Virchow Group	Phase 1/Phase 2
Adocia	Phase 1/Phase 2
Bedford Research Corporation, Inc.

See all becaplermin clinical trials

Recent Litigation for becaplermin

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD.	2023-01-19
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN INC.	2021-07-28

See all becaplermin litigation

Pharmacology for becaplermin

Established Pharmacologic Class	Human Platelet-derived Growth Factor
Chemical Structure	Platelet-Derived Growth Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for becaplermin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for becaplermin Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	5,457,093	2012-10-10	Company disclosures

3) Low Certainty: US Patents for becaplermin Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	10,111,968	2032-02-15	Patent claims search
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	10,118,956	2034-12-01	Patent claims search
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	10,143,755	2033-05-17	Patent claims search

International Patents for becaplermin

Country	Patent Number	Estimated Expiration
Denmark	0859596
Australia	7370796
European Patent Office	0312208

Supplementary Protection Certificates for becaplermin

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
99C0034	Belgium		PRODUCT NAME: BECAPLERMIN; REGISTRATION NO/DATE: EU/1/99/101/001 19990329
SPC/GB99/023	United Kingdom		PRODUCT NAME: BECAPLERMIN; REGISTERED: UK EU/1/99/101/001 19990329
C990016	Netherlands		PRODUCT NAME: BECAPLERMINUM; REGISTRATION NO/DATE: EU/1/99/101/001 19990329